Literature DB >> 3426559

Cellular free cholesterol in Hep G2 cells is only partially available for down-regulation of low-density-lipoprotein receptor activity.

L M Havekes1, E C de Wit, H M Princen.   

Abstract

We have previously shown that in Hep G2 cells and human hepatocytes, as compared with fibroblasts, the low-density lipoprotein (LDL) receptor activity is only weakly down-regulated after incubation of the cells with LDL, whereas incubation with high-density lipoproteins (HDL) of density 1.16-1.20 g/ml (heavy HDL) strongly increased the LDL-receptor activity. To elucidate this difference between hepatocytes and fibroblasts, we studied the cellular cholesterol homoeostasis in relation to the LDL-receptor activity in Hep G2 cells. (1) Interrupting the cholesteryl ester cycle by inhibiting acyl-CoA: cholesterol acyltransferase (ACAT) activity with compound 58-035 (Sandoz) resulted in an enhanced LDL-mediated down-regulation of the receptor activity. (2) The stimulation of the receptor activity by incubation of the cells with cholesterol acceptors such as heavy HDL was not affected by ACAT inhibition. (3) Incubation of the Hep G2 cells with LDL, heavy HDL or a combination of both grossly affected LDL-receptor activity, but did not significantly change the intracellular content of free cholesterol, suggesting that in Hep G2 cells the regulatory free cholesterol pool is small as compared with the total free cholesterol mass. (4) We used changes in ACAT activity as a sensitive (indirect) measure for changes in the regulatory free cholesterol pool. (5) Incubation of the cells with compactin (2 microM) without lipoproteins resulted in a 4-fold decrease in ACAT activity, indicating that endogenously synthesized cholesterol is directed to the ACAT-substrate pool. (6) Incubation of the cells with LDL or a combination of LDL and heavy HDL stimulated ACAT activity 3-5 fold, whereas incubation with heavy HDL alone decreased ACAT activity more than 20-fold. Our results suggest that in Hep G2 cells exogenously delivered (LDL)-cholesterol and endogenously synthesized cholesterol are primarily directed to the cholesteryl ester (ACAT-substrate) pool or, if present, to extracellular cholesterol acceptors (heavy HDL) rather than to the free cholesterol pool involved in LDL-receptor regulation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3426559      PMCID: PMC1148474          DOI: 10.1042/bj2470739

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  32 in total

1.  High-affinity association and degradation of 125I-labelled low density lipoproteins by human hepatocytes in primary culture.

Authors:  V A Kosykh; S N Preobrazhensky; V O Ivanov; V P Tsibulsky; V S Repin; V N Smirnov
Journal:  FEBS Lett       Date:  1985-04-08       Impact factor: 4.124

Review 2.  Role of acyl-CoA: cholesterol acyltransferase in cellular cholesterol metabolism.

Authors:  K E Suckling; E F Stange
Journal:  J Lipid Res       Date:  1985-06       Impact factor: 5.922

3.  HepG2. A human hepatoblastoma cell line exhibiting defects in bile acid synthesis and conjugation.

Authors:  G T Everson; M A Polokoff
Journal:  J Biol Chem       Date:  1986-02-15       Impact factor: 5.157

4.  Stimulation of the LDL receptor activity in the human hepatoma cell line Hep G2 by high-density serum fractions.

Authors:  L M Havekes; D Schouten; E C de Wit; L H Cohen; M Griffioen; V W van Hinsbergh; H M Princen
Journal:  Biochim Biophys Acta       Date:  1986-02-12

5.  Effects of compactin, mevalonate and low-density lipoprotein on 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and low-density-lipoprotein-receptor activity in the human hepatoma cell line Hep G2.

Authors:  L H Cohen; M Griffioen; L Havekes; D Schouten; V van Hinsbergh; H J Kempen
Journal:  Biochem J       Date:  1984-08-15       Impact factor: 3.857

6.  Regulation of low density lipoprotein receptor function in a human hepatoma cell line.

Authors:  A M Leichtner; M Krieger; A L Schwartz
Journal:  Hepatology       Date:  1984 Sep-Oct       Impact factor: 17.425

7.  Inhibition of acyl coenzyme A:cholesterol acyl transferase in J774 macrophages enhances down-regulation of the low density lipoprotein receptor and 3-hydroxy-3-methylglutaryl-coenzyme A reductase and prevents low density lipoprotein-induced cholesterol accumulation.

Authors:  I Tabas; D A Weiland; A R Tall
Journal:  J Biol Chem       Date:  1986-03-05       Impact factor: 5.157

8.  Cultured human hepatocytes. Evidence for metabolism of low density lipoproteins by a pathway independent of the classical low density lipoprotein receptor.

Authors:  S B Edge; J M Hoeg; T Triche; P D Schneider; H B Brewer
Journal:  J Biol Chem       Date:  1986-03-15       Impact factor: 5.157

9.  Liver transplantation to provide low-density-lipoprotein receptors and lower plasma cholesterol in a child with homozygous familial hypercholesterolemia.

Authors:  D W Bilheimer; J L Goldstein; S M Grundy; T E Starzl; M S Brown
Journal:  N Engl J Med       Date:  1984-12-27       Impact factor: 91.245

10.  Regulation of high density lipoprotein receptors in cultured macrophages: role of acyl-CoA:cholesterol acyltransferase.

Authors:  G Schmitz; R Niemann; B Brennhausen; R Krause; G Assmann
Journal:  EMBO J       Date:  1985-11       Impact factor: 11.598

View more
  20 in total

1.  Colestilan decreases weight gain by enhanced NEFA incorporation in biliary lipids and fecal lipid excretion.

Authors:  Kanami Sugimoto-Kawabata; Hiroshi Shimada; Kaoru Sakai; Kazuo Suzuki; Thomas Kelder; Elsbet J Pieterman; Louis H Cohen; Louis M Havekes; Hans M Princen; Anita M van den Hoek
Journal:  J Lipid Res       Date:  2013-02-22       Impact factor: 5.922

2.  Lipoprotein cholesterol uptake mediates up-regulation of bile-acid synthesis by increasing cholesterol 7alpha-hydroxylase but not sterol 27-hydroxylase gene expression in cultured rat hepatocytes.

Authors:  S M Post; J Twisk; L van der Fits; E C de Wit; M F Hoekman; W H Mager; H M Princen
Journal:  Biochem J       Date:  1999-07-15       Impact factor: 3.857

3.  Effect of 25-hydroxycholesterol and bile acids on the regulation of cholesterol metabolism in Hep G2 cells.

Authors:  T L Carlson; B A Kottke
Journal:  Biochem J       Date:  1989-11-15       Impact factor: 3.857

4.  Evidence for sterol-independent regulation of low-density lipoprotein receptor activity in Hep-G2 cells.

Authors:  J L Ellsworth; C Chandrasekaran; A D Cooper
Journal:  Biochem J       Date:  1991-10-01       Impact factor: 3.857

5.  Butyrate stimulates the secretion of apolipoprotein (apo) A-I and apo B100 by the human hepatoma cell line Hep G2. Induction of apo A-I mRNA with no change of apo B100 mRNA.

Authors:  A Kaptein; L Roodenburg; H M Princen
Journal:  Biochem J       Date:  1991-09-01       Impact factor: 3.857

6.  Selective uptake of cholesteryl esters of low-density lipoproteins is mediated by the lipoprotein-binding site in HepG2 cells and is followed by the hydrolysis of cholesteryl esters.

Authors:  L Brissette; M C Charest; L Falstrault
Journal:  Biochem J       Date:  1996-09-15       Impact factor: 3.857

7.  Mathematical modelling of competitive LDL/VLDL binding and uptake by hepatocytes.

Authors:  T Pearson; J A D Wattis; B O'Malley; L Pickersgill; H Blackburn; K G Jackson; H M Byrne
Journal:  J Math Biol       Date:  2008-08-14       Impact factor: 2.259

8.  Low-density lipoproteins are degraded in HepG2 cells with low efficiency.

Authors:  P Lombardi; M Mulder; E de Wit; T J van Berkel; R R Frants; L M Havekes
Journal:  Biochem J       Date:  1993-03-01       Impact factor: 3.857

9.  Dietary fatty acids regulate hepatic low density lipoprotein (LDL) transport by altering LDL receptor protein and mRNA levels.

Authors:  J D Horton; J A Cuthbert; D K Spady
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

10.  Regulation of plasma LDL: the apoB paradigm.

Authors:  Allan D Sniderman; Jacqueline De Graaf; Patrick Couture; Ken Williams; Robert S Kiss; Gerald F Watts
Journal:  Clin Sci (Lond)       Date:  2009-11-23       Impact factor: 6.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.